How to buy CureVac N-V stock | $55.11

CureVac N.V is a biotechnology business based in the US. CureVac N-V shares (CVAC) are listed on the NASDAQ and all prices are listed in US Dollars. CureVac N-V employs 455 staff and has a trailing 12-month revenue of around 0.00.

CureVac N-V stock price (NASDAQ: CVAC)

Use our graph to track the performance of CVAC stocks over time.

CureVac N-V shares at a glance

• Key figures

Information last updated 2021-09-11.

Latest market close	$55.11
52-week range	$43.00 - $151.80
50-day moving average	$63.29
200-day moving average	$84.10
Wall St. target price	$72.64
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.16

Buy CureVac N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy CureVac N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CureVac N-V price performance over time

Historical closes compared with the close of $55.11 from 2021-09-16

1 week (2021-09-10)	-18.33%
1 month (2021-08-18)	-16.54%
3 months (2021-06-18)	-11.03%
6 months (2021-03-18)	-38.44%

1 year (2020-09-18)	5.80%
2 years (2019-09-14)	N/A
3 years (2018-09-14)	N/A
5 years (2016-09-14)	N/A

CureVac N-V financials

Revenue TTM	$48.9 million
Gross profit TTM	$34.7 million
Return on assets TTM	-10.17%
Return on equity TTM	-38.63%
Profit margin	-264.21%
Book value	$3.94
Market capitalisation	$12.6 billion

TTM: trailing 12 months

Shorting CureVac N-V shares

There are currently 4.5 million CureVac N-V shares held short by investors – that's known as CureVac N-V's "short interest". This figure is 12.4% up from 4.0 million last month.

There are a few different ways that this level of interest in shorting CureVac N-V shares can be evaluated.

CureVac N-V's "short interest ratio" (SIR)

CureVac N-V's "short interest ratio" (SIR) is the quantity of CureVac N-V shares currently shorted divided by the average quantity of CureVac N-V shares traded daily (recently around 728954.6474359). CureVac N-V's SIR currently stands at 6.24. In other words for every 100,000 CureVac N-V shares traded daily on the market, roughly 6240 shares are currently held short.

However CureVac N-V's short interest can also be evaluated against the total number of CureVac N-V shares, or, against the total number of tradable CureVac N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CureVac N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CureVac N-V shares in existence, roughly 20 shares are currently held short) or 0.0565% of the tradable shares (for every 100,000 tradable CureVac N-V shares, roughly 57 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CureVac N-V.

Find out more about how you can short CureVac N-V stock.

CureVac N-V share dividends

We're not expecting CureVac N-V to pay a dividend over the next 12 months.

CureVac N-V overview

CureVac N. V. , a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Frequently asked questions

What percentage of CureVac N-V is owned by insiders or institutions?
Currently 51.298% of CureVac N-V shares are held by insiders and 23.459% by institutions. How many people work for CureVac N-V?
Latest data suggests 455 work at CureVac N-V. When does the fiscal year end for CureVac N-V?
CureVac N-V's fiscal year ends in December. Where is CureVac N-V based?
CureVac N-V's address is: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076 What is CureVac N-V's ISIN number?
CureVac N-V's international securities identification number is: NL0015436031